Medicine Recommendations

Care in the last weeks or days of life - Nausea and vomiting in the last days of life AND Agitation/terminal restlessness in the last days of life

Nausea and vomiting

Opioid-induced nausea and vomiting

Schizophrenia (Existing Patients)

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia (New Patients)

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

ADHD in adults

ADHD in children and young adults

Mania, bipolar disorder and recurrent depression

Depressive illness

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Breathlessness

Breathlessness in the last days of life

Short term use in anxiety and insomnia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Short term use in anxiety and insomnia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia or bipolar disorder (NICE TA286 - terminated appraisal)

NICE TA286 - Loxapine Inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)

Treatment of schizophrenia in adults aged 18 and over

Insomnia in those over 55 (short term use only)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

For the Treatment of Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD) in Parkinson’s Disease and Lewy Body Dementia

Children with learning disabilities

Children with ADHD

Children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome

Cerebral palsy

Children with complex neurodevelopmental disorders that the specialist considers eligible

All indications including insomnia and jet lag

For the management of sleep disorders in totally blind patients. 

For the management of sleep disturbance in adult patients with ADHD